India, May 18 -- Catheter Precision, Inc. (VTAK), a medical device and technology company, on Monday reported financial results for the first quarter of 2026, reflecting 200% revenue growth, and provided an update on its recent acquisition.
Following the news, Catheter Precision shares are up over 9.23% at $0.83.
Company Profile
Catheter Precision designs, manufactures, and sells medical technologies for cardiac electrophysiology.
The company's lead product is VIVO (View into Ventricular Onset System), a non-invasive imaging system that offers 3D cardiac mapping to help with localising the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures, and LockeT, a suture retent...